Difference between revisions of "Clomipramine-fluvoxamine"
From Psychiatrienet
| (One intermediate revision by one other user not shown) | |||
| Line 7: | Line 7: | ||
{{StartfluvoxIA}} | {{StartfluvoxIA}} | ||
| info = | | info = | ||
| − | * Fluvoxamine is an inhibitor of CYP2C19, which metabolize | + | * Fluvoxamine is an inhibitor of CYP2C19, which metabolize clomipramine. |
| − | + | * Safe target dose fluvoxamine = 100 mg | |
| − | |||
}} | }} | ||
Latest revision as of 16:06, 20 February 2025
| ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
Switch medication from clomipramine to fluvoxamine[1][2]
Stop clomipramine - Day 1: Decrease with about 25% of the original dose per 3 days.
Start fluvoxamine- Day 6: At approximately 50-25% of the original drug dose start fluvoxamine at 50% of the target dose.
- Day 12: Increase dosage of fluvoxamine to 100% of the target dose.
- Day 17: Increase dosage of fluvoxamine if necessary.
More information- Fluvoxamine is an inhibitor of CYP2C19, which metabolize clomipramine.
- Safe target dose fluvoxamine = 100 mg
- Jump up ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- Jump up ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
